프라임 메디슨(PRME)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.14 (+0.00%), 시가총액 $0.53B, 52주 최저~최고 $1.17 ~ $6.67.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic F
프라임 메디슨의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
프라임 메디슨의 현재 주가는 $3.14 (+0.00%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
프라임 메디슨의 시가총액은 약 $0.53B입니다.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeut